RXMD is in a clear bullish technical posture: at key support with multiple touches over two years and an RSI print under the "30" bull signal level. In other words, it's oversold and triggering key support in a very large time-frame bull trend.
• Telehealth regulations have been dropped to allow it to brace our healthcare system against exponential COVID-19 case growth. • RXMD is currently priced at 0.5x trailing sales, which is extremely cheap, even for a pharmacy play. • This is especially true given that it just posted 56% top-line growth and is moving toward the likely launch of a telemedicine platform. • RXMD is moving toward a NASDAQ or NYSE uplisting.